樂觀
$24.86
情境價格
$21.480
-0.079 (-0.37%)收盤時
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.
UBS
$25
2026-08-04
UBS
2026-08-04
目標價
$25
TD Cowen
$20
2026-08-04
TD Cowen
2026-08-04
目標價
$20
Truist
$23
2026-08-04
Truist
2026-08-04
目標價
$23
UBS
$24
2026-07-28
UBS
2026-07-28
目標價
$24
Truist
$21
2026-07-16
Truist
2026-07-16
目標價
$21
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

SI-BONE Receives FDA Clearance for Onyx System

SI-BONE (SIBN) Q2 2026 Earnings Call Insights

SI-BONE Reports Narrowed Net Loss and Revenue Growth in Q2 2026

SI-BONE Q2 Earnings Exceed Expectations

ViCentra Appoints New CFO and Independent Board Member
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.
4 analysts cover SIBN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.17.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。